Aanjaay Industries Limited (formerly known as Kabra Drugs Limited) returned to profitability in the first quarter of FY26, reporting a net profit after tax of ₹212.30 lakh. This marks a significant turnaround from the net loss of ₹49.98 lakh recorded in the same quarter of the previous fiscal year.

The Indore-based company posted total income from operations of ₹4,629.33 lakh for the quarter ended June 30, 2026, a substantial increase from ₹716.62 lakh in Q1FY25. The pre-tax profit stood at ₹284.01 lakh, unchanged from the figure before exceptional items.

For the full fiscal year FY26, Aanjaay Industries reported total operating income of ₹9,323.27 lakh and a net profit of ₹495.98 lakh. The equity share capital remained stable at ₹2,370.79 lakh throughout the periods reviewed.

What the Numbers Show

The divergence between the sharp rise in operating income and the relatively modest absolute profit figures suggests thin margins during the quarter. While revenue grew more than six-fold year-on-year, the net profit margin for the quarter stands at approximately 4.6% (₹212.30 lakh on ₹4,629.33 lakh), indicating that cost structures or lower-margin business mix may be absorbing much of the top-line growth. The absence of exceptional or extraordinary items confirms that the turnaround was driven purely by operational performance rather than one-off gains.

The company filed these unaudited financial results with stock exchanges pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were published in newspaper advertisements on August 18, 2026.

Kabra Drugs Limited has received approval from the Government of Chhattisgarh to establish a pharmaceutical manufacturing facility at Nava Raipur Pharma Park. The project entails a proposed investment of approximately ₹200 Crore and is expected to generate approximately 250 direct and indirect employment opportunities. This strategic initiative aims to expand the company's manufacturing capacity and support its long-term growth strategy, subject to the execution of definitive agreements and necessary approvals.

The approval, communicated via a Letter of Intent (LOI) received on 12 June 2026, outlines the establishment of a facility dedicated to pharmaceutical and related healthcare manufacturing activities. The company stated that the project is expected to enhance its manufacturing footprint and boost revenue multifold. However, the realization of these benefits remains contingent upon implementation timelines and the receipt of regulatory sanctions.

Project Details and Conditions

The proposed investment is subject to applicable State Government policies, approvals, and sanction orders. The disclosure notes that incentives are roughly 60% on date, though final figures depend on compliance with statutory requirements. The company emphasized that the investment will proceed only after fulfilling all necessary conditions. Key details of the project are outlined below:

Forward-Looking Statements

The company cautioned that certain statements in the disclosure are forward-looking and involve risks and uncertainties. Actual results may differ materially due to factors such as changes in government policies, regulatory approvals, market conditions, and project implementation timelines. Kabra Drugs undertakes no obligation to publicly update these statements except as required by law.